SANTA CRUZ BIOTECHNOLOGY, INC.

CD27L (C-20): sc-1741



BACKGROUND

The tumor necrosis factor (TNF) receptor family is composed of several type I integral membrane glycoproteins that exhibit homology in their cystine-rich extracellular domains. Members of this family include FAS, OX40, CD27 and CD30. Ligands for these receptors are often type II transmembrane glycoproteins, as is the case for CD27 and CD30. CD27 is a homodimeric lymphocytespecific surface antigen present on T and B lymphocytes. Activation of the CD3 complex via the T cell receptor for antigen leads to an increase in CD27 expression. Together, CD27 and its ligand, CD27L, generate co-stimulatory signals required for complete T cell activation. CD30 is a surface marker for neoplastic cells of the Hodgkin's lymphoma and related hematologic malignancies. CD30L has been shown to enhance the proliferation of the Hodgkin's cell line HDLM-2, but exerts antiproliferative effects on large cell anaplastic lymphoma cell lines.

CHROMOSOMAL LOCATION

Genetic locus: CD70 (human) mapping to 19p13.3; Cd70 (mouse) mapping to 17 D.

SOURCE

CD27L (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of CD27L of human origin.

PRODUCT

Each vial contains 200 μ g lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

CD27L (C-20) is available conjugated fluorescein (sc-1741 FITC, 200 µg/ml), for IF, IHC(P) and FCM.

Blocking peptide available for competition studies, sc-1741 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

CD27L (C-20) is recommended for detection of CD27L of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for CD27L siRNA (h): sc-42764, CD27L siRNA (m): sc-42765, CD27L shRNA Plasmid (h): sc-42764-SH, CD27L shRNA Plasmid (m): sc-42765-SH, CD27L shRNA (h) Lentiviral Particles: sc-42764-V and CD27L shRNA (m) Lentiviral Particles: sc-42765-V.


Molecular Weight of CD27L: 29 kDa.


Positive Controls: RAW 264.7 + LPS/PMA cell lysate: sc-2212 or RAW 264.7 whole cell lysate: sc-2211.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

DATA





CD27L (C-20): sc-1741. Western blot analysis of CD27L CD27L (C-20): sc-1741. Western blot analysis of expression in RAW 264.7 whole cell lysate.

human recombinant CD27L fusion protein.

SELECT PRODUCT CITATIONS

1. Wischhusen, J., et al. 2002. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 62: 2592-2599.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed

Try CD27L (G-7): sc-365539 or CD27L (BU69):

sc-65271, our highly recommended monoclonal alternatives to CD27L (C-20).